Is NCT06499857 recruiting in Phoenix, AZ?

Yes, NCT06499857 is currently recruiting participants at its Phoenix, AZ location. This atrial fibrillation clinical trial is actively enrolling qualified participants.

How do I join the atrial fibrillation clinical trial in Phoenix?

To join this clinical trial in Phoenix, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Phoenix clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Atrial Fibrillation Clinical Trial in Phoenix, AZ

About This Atrial Fibrillation Study in Phoenix

The goal of the study is to learn how a weight loss medication called semaglutide, which is used to treat obesity, in addition to standard AF treatment might affect AF, atrial fibrillation severity, and whether it changes the risk of atrial fibrillation recurring after standard AF treatments.

Sponsor: University of Chicago

Who Can Participate

Inclusion Criteria

Age 18-75 years

BMI greater than or equal to 30 kg/m2

Paroxysmal AF or persistent AF, in whom catheter ablation (CA) for AF is expected within 1 year (A group) or in whom catheter ablation is NOT expected within 1 year (M group)

Ability to provide informed consent before any trial-related activities.

Patients with type 2 diabetes mellitus (T2DM) will be included:

If HbA1c (glycated hemoglobin) is less than or equal to 10 %

If the subject is taking basal insulin only or oral hypoglycemic agents or a combination of those.

Patients on SGLT2-inhibitors and TZDs (Thiazolidinedione) will be included if they have been on a stable dose of these medications for at least 6 months

The following protocol will be adopted to adjust insulin secretagogues (sulfonylureas or meglitinides) and insulin during the study (adapted from the Look Ahead Study). Patients will be asked to check their blood glucose (BG) 4 x day (before meals and at bed time) during the dose escalation and dose stabilization phases (weeks 0 to 20) and recommendation of dose adjustments will be immediately sent to their treating physician according to the dose adjustment scale below:

2 blood sugars \<100 mg/dl- reduce meds \[insulin secretagogues (sulfonylureas or meglitinides) and basal insulin\] by 0-50 %

3 blood sugars 80-100 mg/dl- reduce meds \[insulin secretagogues (sulfonylureas or meglitinides) and basal insulin\] by 25-75%

3 blood sugars \<80 mg/dl \> 2 x week or severe hypoglycemia or symptomatic hypoglycemia- reduce meds \[insulin secretagogues (sulfonylureas or meglitinides) and basal insulin\] by 50-100 % Randomization to treatment (active and placebo) will be stratified to balance patients with T2DM across the study arms. After completion of the trial a prespecified subgroup analysis of the patients enrolled affected by T2DM will be performed. For women of child-bearing potential, use of appropriate contraception will be required. In patients that are prescribed amiodarone, standard care practices will be implemented to evaluate for liver and thyroid side effects with baseline liver and thyroid function tests via blood draw and evaluation every 6 months.

Exclusion Criteria

Current use of GLP-1 RA (glucagon-like peptide receptor agonists) or DPP4 (Dipeptidyl peptidase-4)-inhibitors or use within the last 90 days prior to screening

Current antiobesity medication use or use within the last 90 days prior to screening

A self-reported change in body weight of \> 5 kg (11 lb.) within 30 days before screening

History of bariatric surgery

History of type I diabetes mellitus

Current use of prandial insulin

Hospitalization for unstable angina, or TIA (Transient ischemic attack) \< 30 days prior to screening

Pulmonary embolism \< 90 days before screening

MI (myocardial infarction), stroke, etc. \< 90 months prior to screening

Uncontrolled thyroid disease: TSH (Thyroid-stimulating hormone) \> 10.0 mIU/L (Milli-international Units Per Liter) or \< 0.4 mIU/L (Milli-international Units Per Liter) at screening

Active malignancy

Active enrollment in another investigational study that includes any kind of intervention

The receipt of any investigational drug within 90 days prior to this trial.

Inability to comply with study procedures

Acute pancreatitis \< 180 days before screening

History or presence of chronic pancreatitis

CKD (Chronic Kidney Disease) stage 4 (GFR \<30 ml/min)

A personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)

A prior serious hypersensitivity reaction to semaglutide or to any of the excipients in WEGOVY

Chronic inflammatory conditions requiring immunosuppression and/or on glucocorticoids

Previous participation in this trial (received at least one dose of study drug or placebo)

Pregnant, breast-feeding or planning pregnancy

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Phoenix?

Yes, this clinical trial (NCT06499857) has an active research site in Phoenix, AZ that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Atrial Fibrillation Treatment Options in Phoenix, AZ

If you're searching for atrial fibrillation treatment options in Phoenix, AZ, this clinical trial (NCT06499857) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Phoenix research site is actively enrolling participants for this phase 3 clinical trial. You'll receive care from experienced atrial fibrillation specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all atrial fibrillation clinical trials near you to find additional studies recruiting in your area.

Atrial Fibrillation Clinical Trial in Phoenix, AZ

Expert Care in Phoenix

IRB Approved

No-Cost Care

Apply for This Phoenix Location

Why Participate?

Simple Process